| pembrolizumab based treatment |
| pembrolizumab alone | pembrolizumab plus SoC |
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) | | |
es-BC - TNBC - NA - all population 5 | | |
es-BC - TNBC - NA - PDL1 positive 1 | | |
es-BC - Triple negatif (TNBC) - 1st line (L1) | | |
mBC - Triple negative (TNBC) - (neo)adjuvant (NA) | | |
mBC - Triple negative (TNBC) - 1st Line (L1) 1 | | |
mBC - TNBC - L1 - all population 7 | | |
mBC - TNBC - L1 - PDL1 positive 4 | | |
mBC-Triple negative (TNBC) - 2nd Line (L2) 3 | | |
mBC - TNBC - L2 - all population 2 | | |
mBC - TNBC - L2 - PDL1 positive 2 | | |